beta

ALKS

Alkermes plc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

	02-14-2019	10-23-2018	07-26-2018	04-26-2018	02-14-2018	10-26-2017	07-27-2017	04-27-2017
Actual EPS	0.17	-0.08	0.09	-0.2	0.2	-0.09	-0.13	-0.31
Consensus EPS	-0.32	-0.29	-0.11		-0.01	-0.15	-0.26	-0.24
Estimated EPS	-0.32	-0.29	-0.11		-0.01	-0.15	-0.26	-0.24
Number of Estimates	2	2	2		2	3	1	2
EPS Surprise	$0.49	$0.21	$0.20		$0.21	$0.06	$0.13	-$0.07

Stats

Summary

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Market Cap: 9.2 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.alkermes.com

Shares Outstanding: 154 Million

Float: 152 Million

Dividend: 0.0 (0.0%)

Beta: 1.986142

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 11.6 Million

Ethical Flags

Longest drawdown: 828 trading days

From: 2015-12-28 To: 2019-02-21

Lowest Point:

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

DUBLIN , Feb. 20, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the SVB Leerink Global Healthcare Conferenceon Wednesday, Feb. 27, 2019 at 2:30 p.m. ET ( 7:30 p.m. … read more...

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies

via: PR Newswire at 2019-02-19 07:00:00:000

-- Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models -- DUBLIN and BOULDER, Colorado , Feb. 19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies … read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Start Time: 08:30 End Time: 09:37 Alkermes plc (ALKS) Q4 2018 Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Jim Robinson - President and COO Sandy Coombs - Senior Director of IR Confe… read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

NEW YORK , Feb.14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment of Arlo's Ultra camera would be delayed due to "a quality issue… read more...

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes ( ALKS ) Q4 results : Revenues: $315.8M (+14.7%); Manufacturing and royalty revenues: $167.4M (+20.7%); Product sales: $132.7M (+27.7%); R&D revenue: $15.6M; License revenues: $0.1M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read mo… read more...

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes (NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.34 beats by $0.38 ; GAAP EPS of -$0.06 beats by $0.38 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports 2018 GAAP Net Loss per Share of $0.90 and Diluted Non-GAAP Earnings per Share of $0.61 &#xA… read more...

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, (Alkermes or the Company) (NASDAQ:&… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Notable earnings before Thursday's open

via: SeekingAlpha at 2019-02-13 17:30:30:000

AAN , AEE , AER , AGIO , ALE , ALKS , ARCH , AVP , AZN , BAM , BCOR , BGCP , BLMN , BWA , CBB , CCEP , CME , COWN , CYBR , DGX , DNOW , DUK , EEX , EPAM , EQM , EQT , FAF , GEO , GLOG , GNRC , GOOS , GTLS , HII , HPP , INCY , IQV , IRM , KO , LECO , M… read more...

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS)

via: Business Wire at 2019-02-12 16:11:00:000

Law Offices of Howard G. Smithreminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc. (Alkermes or the Company) (NASDAQ: ALKS ) securities b… read more...

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS)

via: Business Wire at 2019-02-12 16:11:00:000

Alkermes Is Still An Attractive Pick

via: SeekingAlpha at 2019-02-11 14:22:50:000

The past few days have proved to be disappointing for the mental health and addiction-focused company, Alkermes ( ALKS ), with share prices slumping down by almost 6.74% from $33.08 on February 1. This month opened with the company receiving complete response letter or CRL from FDA related t… read more...

Best Odds Of Good Capital Gain In Next 3 Months

via: SeekingAlpha at 2019-02-11 12:42:46:000

You are, or should be, an odds-player And you need a good source of odds-ranking. The Daily Racing Form wont do it. Stock price handicappers are much more likely to be that source than the Wall Street Journal or Investors Daily. But the handicappers dont publish anythin… read more...

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

DUBLIN , Feb. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Feb. 14, 2019 , to discuss the company's fourth quarter and year-end2018 financial results. Management will… read more...

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)

via: Business Wire at 2019-02-06 11:00:00:000

Glancy Prongay & Murray LLP (GPM), a global investors rights law firm,announces that a class action lawsuit has been filed on behalf of investors that acquired Alkermes plc, Inc. (Alkermes or the Company) (NASDAQ: ALKS ) securities… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)

via: Business Wire at 2019-02-05 19:03:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Alkermes plc, Inc. (NASDAQ: ALKS ) (Alkermes or the Company) securities between February 17, 2017 and November 1, 2018 , inclusive … read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)

via: Business Wire at 2019-02-05 19:03:00:000

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes plc (NASDAQ: ALKS ) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

DUBLIN , Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for theadjunctive treatment of major dep… read more...

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

Biotech Bio Series #5: Stay Clear Of Biogen

via: SeekingAlpha at 2019-01-28 20:00:43:000

This is the fifth article of the Biotech Bio Series. Pharmaceuticals and biotechnology are some of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug… read more...

Biotech Bio Series #5: Stay Clear Of Biogen

via: SeekingAlpha at 2019-01-28 20:00:43:000

Biotech Bio Series #5: Stay Clear Of Biogen

via: SeekingAlpha at 2019-01-28 20:00:43:000

New Hope For Acorda Therapeutics In 2019

via: SeekingAlpha at 2019-01-28 16:07:55:000

Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,… read more...

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important February 25th Deadline - ALKS

via: PR Newswire at 2019-01-25 18:48:00:000

NEW YORK , Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ: ALKS) from February 17, 2017 through November 1, 2018 , inclus… read more...

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important February 25th Deadline - ALKS

via: PR Newswire at 2019-01-25 18:48:00:000

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important February 25th Deadline - ALKS

via: PR Newswire at 2019-01-25 18:48:00:000

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-25 16:39:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-25 16:39:00:000

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-25 16:39:00:000

Key events next week - healthcare

via: SeekingAlpha at 2019-01-25 07:35:12:000

Noteworthy events during the week of January 27 - February 2 for healthcare investors. More news on: ProQR Therapeutics, GeoVax Labs, Inc., Sierra Oncology, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-01-25 07:35:12:000

Key events next week - healthcare

via: SeekingAlpha at 2019-01-25 07:35:12:000

Jefferies bearish on biotechs, sees 6% near-term downside

via: SeekingAlpha at 2019-01-23 14:05:04:000

Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...

Jefferies bearish on biotechs, sees 6% near-term downside

via: SeekingAlpha at 2019-01-23 14:05:04:000

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

Massachusetts AG after Purdue Pharma owners for role in opioid crisis

via: SeekingAlpha at 2019-01-16 07:43:42:000

Massachusetts Attorney General Maura Healey has filed an amended lawsuit against privately held Purdue Pharma aimed at holding members of the controlling Sackler family personally responsible for its role in the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIV… read more...

Massachusetts AG after Purdue Pharma owners for role in opioid crisis

via: SeekingAlpha at 2019-01-16 07:43:42:000

Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

via: PR Newswire at 2019-01-16 07:00:00:000

2018 Competitive Grants Program Awards Approximately $400,000 for Research Projects Focused on Substance Use Disorders DUBLIN , Jan. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the ALKERMES PATHWAYS RESEARCH AWA… read more...

Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

via: PR Newswire at 2019-01-16 07:00:00:000

SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)

via: PR Newswire at 2019-01-10 16:04:00:000

PHILADELPHIA , Jan. 10, 2019 /PRNewswire/ --Berger Montague announced today that Alkermes (NASDAQ: ALKS) and its CEO and CFO have been accused of federal securities law violations in a class action filed in the U.S. District Court for the Eastern District of New York . The lawsuit … read more...

SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)

via: PR Newswire at 2019-01-10 16:04:00:000

SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)

via: PR Newswire at 2019-01-10 16:04:00:000

Alkermes (ALKS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 05:56:26:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes (ALKS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 05:56:26:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes (ALKS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 05:56:26:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-09 09:48:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS). If you invested in Alkermes stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/AL… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS

via: PR Newswire at 2019-01-08 19:47:00:000

NEW YORK , Jan. 9, 2019 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors ofAlkermes plc ("Alkermes" or the "Company")(NASDAQ: ALKS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 8… read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Alkermes plc to Contact the Firm

via: Business Wire at 2019-01-08 12:18:00:000

Robbins Arroyo LLP: Alkermes Public Limited Company (ALKS) Misled Shareholders According to a Recently Filed Class Action

via: Business Wire at 2019-01-08 12:08:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Alkermes Public Limited Company (NASDAQ: ALKS) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 17, 2017 and November 1, 2018. Al… read more...

Investor Alert: Kaplan Fox Announces Investigation Of Alkermes plc

via: PR Newswire at 2019-01-08 10:36:00:000

NEW YORK , Jan. 8, 2019 /PRNewswire/ --Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS). Investors who purchased Alkermes securities between February 17, 2017 and… read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm

via: PR Newswire at 2019-01-07 13:49:00:000

NEW YORK , Jan. 7, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS). If you invested in Alkermes stock or options and would like to discuss… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-04 12:46:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-04 12:46:00:000

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-04 12:46:00:000

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-03 16:53:00:000

Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference

via: PR Newswire at 2019-01-02 16:00:00:000

DUBLIN , Jan. 2, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 at 9:30 a.m. PT ( 12:30 p.m. ET / 5:30 p.m. GMT ) from the We… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm,announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes plc("Alkermes" or the "… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Alkermes cut to Sell at Goldman

via: SeekingAlpha at 2018-12-18 17:52:31:000

Recent checks show ALKS-3831 is "unlikely to be practice changing" for schizophrenia, says analyst Terence Flynn, downgrading Alkermes (NASDAQ: ALKS ) to Sell from Neutral. More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes cut to Sell at Goldman

via: SeekingAlpha at 2018-12-18 17:52:31:000

Alkermes cut to Sell at Goldman

via: SeekingAlpha at 2018-12-18 17:52:31:000

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes plc (NASDAQ: ALKS ) has filed a New Drug Application (NDA) with the FDA seeking approval for VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcare stocks news, Read more … read more...

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

DUBLIN and CAMBRIDGE, Massachusetts , Dec. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate&#xA… read more...

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc - ALKS

via: Business Wire at 2018-11-15 16:13:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc. (NASDAQ:ALKS) resulting from allegations that Alkermes may have issued materially misleading business information to the investing publ… read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

via: PR Newswire at 2018-11-01 18:47:00:000

DUBLIN , Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's … read more...

FDA Ad Com thumbs down on Alkermes' buprenorphine/samidorphan

via: SeekingAlpha at 2018-11-01 16:01:55:000

FDA advisory committees voted 20-3 against approval for Alkermes' (NASDAQ: ALKS ) buprenorphine and samidorphan sublingual tablets for the adjunctive treatment of major depressive disorder. More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Trading in Alkermes Ordinary Shares Halted Today

via: PR Newswire at 2018-11-01 07:00:00:000

DUBLIN , Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Comm… read more...

Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD

via: SeekingAlpha at 2018-10-30 08:04:40:000

Alkermes plc (NASDAQ: ALKS ) is down 6% premarket on light volume in response to the release of briefing documents for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for buprenorphine and samidorphan sublingual tablets… read more...

Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD

via: SeekingAlpha at 2018-10-30 08:04:40:000

Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry

via: PR Newswire at 2018-10-29 13:19:00:000

ALKS 5461 DemonstratedConsistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies New Drug Application for ALKS 5461 Currently Under FDA Review With Target Action Date of Jan. 31, 2019 DUBLIN , … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

Alkermes (ALKS) CEO Richard Pops on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-23 15:17:04:000

Alkermes Plc (ALKS) Q3 2018 Earnings Conference Call October 23, 2018 8:30 AM ET Executives Sandy Coombs Co-Head of Investor Relations Jim Frates Senior Vice President, Chief Financial Officer and Treasurer Richard Pops Chairman and Chief Executive Offi… read more...

Alkermes plc 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-23 10:16:06:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q3 earnings Read more … read more...

Alkermes Q3 revenues up 14%

via: SeekingAlpha at 2018-10-23 07:50:20:000

Alkermes ( ALKS ) Q3 results: Revenues: $248.7M (+14.4%); Manufacturing and royalty revenues: $116.4M (-5.1%); Product sales: $116M (+23.8%); R&D revenue: $16.3M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Alkermes beats by $0.14, beats on revenue

via: SeekingAlpha at 2018-10-23 07:01:41:000

Alkermes (NASDAQ: ALKS ): Q3 Non-GAAP EPS of $0.07 beats by $0.14 ; GAAP EPS of -$0.22 beats by $0.24 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-23 07:00:00:000

Third Quarter Revenues Increased to $248.7 Million , Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports GAAP Net Loss per Share of $0.22 and Diluted Non-GAAP Earnings per Share of $0.07 &#… read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-10-22 17:30:35:000

ABG , ALKS , ARCH , ASTE , ATI , AVY , AXE , BIIB , CAT , CIT , CNC , DGX , EDU , FBC , FITB , FNB , GATX , GLW , GPK , HBAN , HOG , HUBB , JBLU , LMT , LPT , MBFI , MCD , MMM , NEE , PCAR , PHM , PNR , PPBI , RF , SLCA , SNV , TRU , UTX , VZ , WAT , … read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-16 16:01:00:000

DUBLIN , Oct. 16, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Tuesday, Oct. 23, 2018 , to discuss the company's third quarter 2018 financial results. Management will also provide an up… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

via: PR Newswire at 2018-09-05 07:00:00:000

--ALKERMES Inspiration Grants Program Will Award Up to$1 Millionfor the Development or Expansion of Innovative Programs-- --Applications Now Open for Submission ThroughOct. 2, 2018-- DUBLIN , Sept. 5, 2018 /PRNews… read more...

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

via: PR Newswire at 2018-09-05 07:00:00:000

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

FDA clamps down on opioid-peddling websites

via: SeekingAlpha at 2018-08-28 10:57:45:000

The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

FDA awards contract to develop guidelines for opioid prescribing

via: SeekingAlpha at 2018-08-22 11:16:23:000

The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

White House proposing cuts in opioid production

via: SeekingAlpha at 2018-08-16 15:24:55:000

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

Alkermes - 2018 Shaping Into Excellent Year

via: SeekingAlpha at 2018-07-30 08:49:44:000

Alkermes ( ALKS ) recently reported Q2, 2018 earnings. With solid revenues and significant near term catalysts, 2018 is turning into an excellent year. This article explores Alkermes' investment merits. Alkermes' Vivitrol generates solid increasing revenues. Alkermes' Vivitrol is an oldie … read more...

Alkermes - 2018 Shaping Into Excellent Year

via: SeekingAlpha at 2018-07-30 08:49:44:000

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-07-25 17:30:13:000

AAL , AAN , AB , ABMD , ADNT , AGN , AIMC , ALK , ALKS , ALLE , ALLY , ALXN , APD , ARD , ASPS , AUO , AXE , AXTA , AZN , BANC , BAX , BC , BMS , BMY , BUD , BWA , CELG , CFR , CMCSA , CME , CMS , CNHI , COLB , COP , COR , COWN , CPG , CRI , CRR , CTS… read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA&#xAE; for Schizophrenia

via: PR Newswire at 2018-07-02 07:01:00:000

DUBLIN , July 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injec… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

FDA OKs first non-opioid treatment for opioid withdrawal

via: SeekingAlpha at 2018-05-16 16:44:42:000

The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...